Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy,John F. Seymour,Pierre Feugier,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,John Catalano,Pauline Brice,François Lemonnier,Alejandro Martín,Olivier Casasnovas,Lars Møller Pedersen,Véronique Dorvaux,David M. Simpson,Sirpa Leppä,Jean Gabarre,Maria Gomes da Silva,Sylvie Glaisner,Loic Ysebaert,Anne Vekhoff,Tanin Intragumtornchai,Steven Le Gouill,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Jonathan Farhi,Harald Zeuner,Hervé Tilly,Gilles Salles

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

2019

PURPOSEThe PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free sur...

Keywords:

Follicular lymphoma
Pathology
Internal medicine
Rituximab
Oncology
Progression-free survival
Medicine
Vincristine
long term results
Cyclophosphamide
Prednisone
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations